Begüm Avcı1, Tuba Kurt2, Fatma Aydın3, Elif Çelikel2, Zahide Ekinci Tekin2, Müge Sezer2, Nilüfer Tekgöz2, Cüneyt Karagöl2, Serkan Coşkun2, Melike Mehveş Kaplan2, Umut Selda Bayrakçı4, Banu Acar2. 1. Department of Pediatric Nephrology, Başkent University Faculty of Medicine, M.D., Gazi Paşa Mah. Baraj Cad. No:7, Seyhan, Adana, Turkey. begumavcidr@gmail.com. 2. Department of Pediatric Rheumatology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey. 3. Department of Pediatric Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey. 4. Faculty of Medicine, Department of Pediatric Nephrology, Ankara Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Immunoglobulin A vasculitis with nephritis (IgAVN) is the most serious complication affecting long-term prognosis. Understanding the risk factors and markers for the development of IgAVN is essential. The aim of this study is to identify IgAVN-associated factors and to evaluate the usability of Pediatric Vasculitis Activity Score (PVAS) at diagnosis as an early marker for the development of IgAVN. METHODS: We conducted a retrospective case-control study of 314 patients divided into two groups: those with nephritis (IgAVN) and without nephritis (non-IgAVN). The groups were compared in terms of clinical symptoms, laboratory values, and PVAS values. RESULTS: In total, 18.5% of the patients had IgAVN; they were older than the non-IgAVN patients (median age was 8.8, p < 0.05). Arthritis/arthralgia, abdominal pain, and intestinal bleeding were more common, systolic and diastolic BP were higher in IgAVN (p < 0.05). CRP, serum creatinine, and urine protein/Cr, PVAS were higher, while serum albumin was lower in IgAVN (p < 0.05). The receiver operator characteristic curve (ROC) analysis showed that IgAV patients with a determined cut-off PVAS value greater than 3 had 70.7% sensitivity in predicting whether or not they would develop IgAVN. Logistic regression analysis found that PVAS > 3 and low serum albumin at the time of diagnosis were independent risk factors for IgAVN. CONCLUSION: Our study revealed that PVAS > 3 at diagnosis is an independent predictor of IgAVN. Patients with PVAS > 3 should be followed more closely to ensure early diagnosis and management of IgAVN. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Immunoglobulin A vasculitis with nephritis (IgAVN) is the most serious complication affecting long-term prognosis. Understanding the risk factors and markers for the development of IgAVN is essential. The aim of this study is to identify IgAVN-associated factors and to evaluate the usability of Pediatric Vasculitis Activity Score (PVAS) at diagnosis as an early marker for the development of IgAVN. METHODS: We conducted a retrospective case-control study of 314 patients divided into two groups: those with nephritis (IgAVN) and without nephritis (non-IgAVN). The groups were compared in terms of clinical symptoms, laboratory values, and PVAS values. RESULTS: In total, 18.5% of the patients had IgAVN; they were older than the non-IgAVN patients (median age was 8.8, p < 0.05). Arthritis/arthralgia, abdominal pain, and intestinal bleeding were more common, systolic and diastolic BP were higher in IgAVN (p < 0.05). CRP, serum creatinine, and urine protein/Cr, PVAS were higher, while serum albumin was lower in IgAVN (p < 0.05). The receiver operator characteristic curve (ROC) analysis showed that IgAV patients with a determined cut-off PVAS value greater than 3 had 70.7% sensitivity in predicting whether or not they would develop IgAVN. Logistic regression analysis found that PVAS > 3 and low serum albumin at the time of diagnosis were independent risk factors for IgAVN. CONCLUSION: Our study revealed that PVAS > 3 at diagnosis is an independent predictor of IgAVN. Patients with PVAS > 3 should be followed more closely to ensure early diagnosis and management of IgAVN. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo Journal: Ann Rheum Dis Date: 2005-12-01 Impact factor: 19.103
Authors: Kimberly A Morishita; Lakshmi N Moorthy; Joanna M Lubieniecka; Marinka Twilt; Rae S M Yeung; Mary B Toth; Susan Shenoi; Goran Ristic; Susan M Nielsen; Raashid A Luqmani; Suzanne C Li; Tzielan Lee; Erica F Lawson; Mikhail M Kostik; Marisa Klein-Gitelman; Adam M Huber; Aimee O Hersh; Dirk Foell; Melissa E Elder; Barbara A Eberhard; Paul Dancey; Sirirat Charuvanij; Susanne M Benseler; David A Cabral Journal: Arthritis Rheumatol Date: 2017-06-09 Impact factor: 10.995
Authors: C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani Journal: Ann Rheum Dis Date: 2008-12-03 Impact factor: 19.103
Authors: Pavla Dolezalova; Fiona E Price-Kuehne; Seza Özen; Susanne M Benseler; David A Cabral; Jordi Anton; Jürgen Brunner; Rolando Cimaz; Katheleen M O'Neil; Carol A Wallace; Nicholas Wilkinson; Despina Eleftheriou; Erkan Demirkaya; Marek Böhm; Petra Krol; Raashid A Luqmani; Paul A Brogan Journal: Ann Rheum Dis Date: 2012-10-25 Impact factor: 19.103
Authors: Ana P Spizzirri; Carlos J Cobeñas; Laura F Alconcher; Néstor Murray; Claudia Zarate; Laura Curutchet; Emanuel De Rose; María José Gogorza; Lucas Lucarelli; Javier Ruscasso; Laura Lombardi; Priscila Pereyra; Javier Zalba; Paula Risso; Angela Suarez Journal: Pediatr Nephrol Date: 2022-05-07 Impact factor: 3.651